Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children.
2019
This open-label, single-arm, prospective cohort trial is the first phase 3 safety study to describe outcomes in children treated with dabigatran etexilate for secondary venous thromboembolism (VTE) prevention. Eligible children aged 12 to 3 months to 3 months to <18 years with persistent VTE risk factor(s).
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
38
References
25
Citations
NaN
KQI